TRIM24 and cancer: Given that older age of IIM onset is associated with CAM regardless of autoantibody positivity [15], and anti-TIF1-Ab positivity confers an increased risk, detailed screening for cancer in anti-TIF1-Ab-positive patients ≥39 years of age is advocated.